Says macro environment has been highly dynamic and challenging over the past two years. Says supply chain continues to face challenges. Sees $2B in covid testing sales in FY23. Says expects to see continued strong performance in EPD. Says realized significant hedging gains last year that won’t repeat this year. Comments taken from Q4 earnings conference call.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on ABT:
- Abbott Delivers Better-than-Expected Q4 Earnings
- Abbott Reports Fourth-Quarter and Full-Year 2022 Results; Issues 2023 Financial Outlook
- Abbott CEO says ‘R&D pipeline continues to be highly productive’
- Abbott sees FY23 adjusted EPS $4.30-$4.50, consensus $4.40
- Abbott reports Q4 adjusted EPS $1.03, consensus 92c